Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up

References

• Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17: 324–30
   PubMed Web of Science ®Google Scholar
• Sartor RB. How relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? [review]. Aliment Pharmacol Ther 1997; 11 Supply 3: 89–96
   Web of Science ®Google Scholar
• Sartor RB. Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis [review]. Aliment Pharmacol Ther 1997; 11 Suppl 3: 17–22
   PubMed Web of Science ®Google Scholar
• Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Jr, Balish E, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945–53
   PubMed Web of Science ®Google Scholar
• Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977; 14: 333–41
   PubMed Web of Science ®Google Scholar
• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733–44
   PubMed Web of Science ®Google Scholar
• Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253–61
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric flora are necessary for development of spontaneous colitis and immune system activation in IL-10- deficient mice. Infect Immun 1998; 66: 5224–31
   PubMed Web of Science ®Google Scholar
• Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997; 150: 91–7
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603–6
   PubMed Web of Science ®Google Scholar
• Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522–5
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993; 14:342: 412–7
   Web of Science ®Google Scholar
• Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 331–40
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417–29
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79–83
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002; 17: 849–53
   PubMed Web of Science ®Google Scholar
• Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 1961; 120: 393–407
   Google Scholar
• Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981; 75: 816–21
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067–70
   PubMed Web of Science ®Google Scholar
• Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380–4
   PubMed Web of Science ®Google Scholar
• Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210–2
   PubMed Web of Science ®Google Scholar
• Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 123–9
   PubMed Web of Science ®Google Scholar
• Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993; 7: 155–8
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43–6
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454–6
   PubMed Web of Science ®Google Scholar
• Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998; 115: 1072–8
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220–1
   PubMed Web of Science ®Google Scholar
• Raleigh J. Chemotherapy of tuberculosis. Mycobacteria: a source book, G Kubica, L Wayne. Marcel Dekker, New York 1984; 15: 1007–20
   Google Scholar
• Unge P. What other regimens are under investigation to treat Helicobacter pylori infection?. Gastroenterology 1997; 113: S131–S48
   PubMed Web of Science ®Google Scholar